VLA Valneva SE
Financings ·
Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale.
Valneva agreed on April 29, 2026 to sell 15,893,817 new shares, each with a warrant, for €37 million. The warrants could add about €47 million if every one is exercised, at €2.96 each.
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases. It currently markets three proprietary travel vaccines: IXIARO, DUKORAL and IXCHIQ. IXIARO is indicated for the prevention of Japanese encephalitis in travelers and military personnel, DUKORAL for the prevention of cholera, and IXCHIQ for chikungunya, which is approved under accelerated approval in Europe, Canada, Brazil and the United Kingdom. In January 2026 the company voluntarily withdrew the Biologics License Application and the Investigational New Drug application for IXCHIQ in the United States. Its clinical pipeline includes VLA15, a Phase 3 Lyme disease vaccine candidate developed with Pfizer, which the text describes as the only Lyme vaccine candidate in late-stage trials. The company also has S4V2, a Phase 2 tetravalent bioconjugate candidate against Shigella, developed with LimmaTech Biologics AG, and VLA1601, a Phase 1 Zika vaccine candidate. Valneva has manufacturing facilities across Europe, including BioSafety Level 3 capacity, and its subsidiaries include Valneva Scotland Ltd. and Valneva Sweden AB. The text says it will only consider further development of VLA1601 if concrete private and public funding opportunities materialize.
| Product or program | What it is | Stage |
|---|---|---|
| IXIARO | Vaccine for prevention of Japanese encephalitis in travelers and military personnel | marketed |
| DUKORAL | Vaccine for prevention of cholera and travelers' diarrhea in some markets | marketed |
| IXCHIQ (VLA1553) | Single-dose live-attenuated vaccine against chikungunya | approved under accelerated approval in Europe, Canada, Brazil and the UK |
| VLA15 | Vaccine candidate against Lyme disease, developed with Pfizer | Phase 3 |
| S4V2 (Shigella4V2) | Tetravalent bioconjugate vaccine candidate against shigellosis, with LimmaTech | Phase 2 |
| VLA1601 | Vaccine candidate against Zika virus | Phase 1 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | €174.7 million | €169.6 million |
| Research and development | €85.3 million | €74.1 million |
| Net income (loss) | -€115.2 million | -€12.2 million |
| Cash from operations | -€52.9 million | -€67.2 million |
| Cash and equivalents | €109.7 million | €168.3 million |
Our latest story on this, dated Jun 4, 2026: "Valneva registers resale of up to 31,787,634 ordinary shares by selling holders". The story links the filing or release it is based on. Read the story.
Valneva SE trades under the ticker VLA on EURONEXT.
Valneva SE is listed on EURONEXT. Our directory also records these other listings: BSESOF:AYJ; DUS:AYJ; EUROTLX:4VLA; FWB:AYJ; GETTEX:AYJ; HAM:AYJ; HAN:AYJ; LS:A0MVJZ; LSE:0OB3; LSX:A0MVJZ; MUN:AYJ; NASDAQ:VALN; SWB:AYJ; TRADEGATE:AYJ; VIE:VLA; XETR:AYJ.
The SEC Central Index Key (CIK) for Valneva SE is 1836564. Its filings are on SEC EDGAR.
173,539,745 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-17.
Our directory records Valneva SE under France.
Our directory classifies Valneva SE as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Valneva SE is FR0004056851.
aibio.space lists Valneva SE among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as I0.
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases. It currently markets three proprietary travel vaccines: IXIARO, DUKORAL and IXCHIQ.
IXIARO: Vaccine for prevention of Japanese encephalitis in travelers and military personnel Stage: marketed.
DUKORAL: Vaccine for prevention of cholera and travelers' diarrhea in some markets Stage: marketed.
Our latest story on Valneva, dated Jun 4, 2026: "Valneva registers resale of up to 31,787,634 ordinary shares by selling holders". Valneva filed a Form F-3 on June 4, 2026 to register the resale of up to 31,787,634 ordinary shares tied to its April 29 private placement. Valneva says it will receive no proceeds from the resale. Source.
SEC records list Valneva SE's filer category as: Accelerated filer.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio